The incidence of myelofibrosis (MF) among the three major Philadelphia chromosome-negative chronic myeloproliferative disorders, i.e. essential thrombocythaemia (ET), polycythaemia vera (PV) and chronic idiopathic myelofibrosis (CIMF), is not well documented since the diagnostic criteria have recently been redefined by the WHO. Therefore we performed a retrospective analysis of follow-up biopsies of 275 patients with ET, PV and CIMF according to the WHO classification of chronic myeloproliferative disorders. In the diagnostic bone marrow biopsies, MF was observed in 57 of the 136 CIMF patients (42%), 4 of the 73 PV patients (5%) and none of the 66 patients with ET. Within a median observation time of 2.9 years, 34 of the 79 patients with CIMF (43%), 13 of the 69 patients with PV (19%) and 1 of the 66 patients with ET (1.5%) – each initially without MF – developed MF regardless of myelosuppressive therapy.

Keywords:
Myelofibrosis, Myelofibrosis, chronic idiopathic, Polycythaemia vera, Thrombocythaemia, essential
1.
Spivak JL, Barosi G, Tognoni G, Barbui T, Finazzi G, Marchioli R, Marchetti M: Chronic myeloproliferative disorders. Hematology 2003;200–224.
2.
Michiels JJ, Kutti J, Stark P, Bazzan M, Gugliotta L, Marchioli R, Griesshammer M, van Genderen PJJ, Brière J, Kiladjian JJ, Barbui T, Finazzi G, Berlin NI, Pearson TC, Green AC, Fruchtman SM, Silver RT, Hansmann E, Wehmeier A, Lengfelder E, Landolfi R, Kvasnicka HM, Hasselbach H, Cervantes F, Reilly JT, Demory JL, Gisslinger B, Guardiola P, Martyré MC, Le Bousse-Kerdilès MC, Thiele J: Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia with myelofibrosis. Neth J Med 2003;54:46–62.
3.
Kreft A, Weiss M, Wiese B, Choritz H, Buhr T, Büsche G, Georgii A: Chronic idiopathic myelofibrosis: Prognostic impact of myelofibrosis and clinical parameters on event-free survival in 122 patients who presented in prefibrotic and fibrotic stages. Ann Hematol 2003;82:605–611.
4.
Barosi G, Ambrosetti A, Finelli C, Grossi A, Leoni P, Liberato NL, Petti MC, Pogliani E, Ricetti M, Rupoli S, Visani G, Tura S: The Italian consensus conference on diagnostic criteria for myelofibrosis with myeloid metaplasia. Br J Haematol 1999;104:730–737.
5.
Tefferi A: The Philadelphia chromosome negative chronic myeloproliferative disorders: A practical overview. Mayo Clin Proc 1998;73:1177–1184.
6.
Murphy S, Peterson P, Iland H, Laszlo J: Experience of the Polycythemia Vera Study Group with essential thrombocythemia: A final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997;34:29–39.
7.
Thiele J, Kvasnicka HM, Diehl V, Fischer R, Michiels JJ: Clinicopathological diagnosis and differential criteria of thrombocythemia in various myeloproliferative disorders by histopathology, histochemistry and immunostainings from bone marrow biopsies. Leuk Lymphoma 1999;33:207–218.
8.
Georgii A, Büsche G, Kreft A: The histopathology of chronic myeloproliferative diseases. Baillières Clin Haematol 1998;11:721–749.
9.
Thiele J, Pierre R, Imbert M, Vardiman JW, Brunning RD, Flandrin G: Chronic idiopathic myelofibrosis; in Jaffe ES, Harris NL, Stein H, Vardiman JW (eds): World Health Organization Classification of Tumors: Pathology and Genetics of Tumours of the Haematopoietic and Lymphoid Tissues. Lyon, IARC Press, 2001, pp 35–38.
10.
Imbert M, Pierre R, Thiele J, Vardiman JW, Brunning RD, Flandrin G: Essential thrombocythaemia; in Jaffe ES, Harris NL, Stein H, Vardiman JW (eds): World Health Organization Classification of Tumors: Pathology and Genetics of Tumours of the Haematopoietic and Lymphoid Tissues. Lyon, IARC Press, 2001, pp 39–41.
11.
Pierre R, Imbert M, Thiele J, Vardiman JW, Brunning RD, Flandrin G: Polycythaemia vera; in Jaffe ES, Harris NL, Stein H, Vardiman JW (eds): World Health Organization Classification of Tumors: Pathology and Genetics of Tumours of the Haematopoietic and Lymphoid Tissues. Lyon, IARC Press, 2001, pp 32–34.
12.
Thiele J, Kvasnicka HM: Chronic myeloproliferative disorders with thrombocythemia: A comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol 2003;82:148–152.
13.
Thiele J, Imbert M, Pierre R, Vardiman JW, Brunning RD, Flandrin G: Chronic myeloproliferative disease, unclassifiable; in Jaffe ES, Harris NL, Stein H, Vardiman JW (eds): World Health Organization Classification of Tumors: Pathology and Genetics of Tumours of the Haematopoietic and Lymphoid Tissues. Lyon, IARC Press, 2001, pp 58–59.
14.
Kvasnicka HM, Thiele J, Werden C, Zankovich R, Diehl V, Fischer R: Prognostic factors in idiopathic (primary) osteomyelofibrosis. Cancer 1997;80:708–719.
15.
Büsche G, Georgii A, Duensing A, Schmeil A, Schlué J, Kreipe H-H: Evaluating the volume ratio of bone marrow affected by fibrosis: A parameter crucial for the prognostic significance of marrow fibrosis in chronic myeloid leukemia. Hum Pathol 2003;34:391–401.
16.
Le Bousse-Kerdilès MC, Martyré MC: Myelofibrosis: Pathogenesis of myelofibrosis with myeloid metaplasia. Springer Semin Immunopathol 2000;21:491–508.
17.
Groopman JE: The pathogenesis of myelofibrosis in myeloproliferative disorders. Ann Intern Med 1980;92:857–858.
18.
Kreft A, Wiese B, Weiss M, Choritz H, Buhr T, Büsche G, Georgii A: Analysis of risk factors of the evolution of myelofibrosis in pre-fibrotic chronic idiopathic myelofibrosis: A retrospective study based on follow-up biopsies of 70 patients by using the RECPAM method. Leuk Lymphoma 2004;45:553–559.
19.
Buhr T, Georgii A, Schuppan O, Amor A, Kaloutsi V: Histologic findings in bone marrow biopsies of patients with thrombocythemic cell counts. Ann Hematol 1992;64:286–291.
20.
Thiele J, Kvasnicka HM, Schmitt-Graeff A, Zirbes TK, Birnbaum F, Kressmann C, Melguizo-Grahmann M, Frackenpohl H, Sprungmann C, Leder L-D, Diehl V, Zankovich R, Schaefer HE, Niederle N, Fischer R: Bone marrow features and clinical findings in chronic myeloid leukemia – A comparative, multicenter, immunohistological and morphometric study on 614 patients. Leuk Lymphoma 2000;36:295–308.
21.
Kreft A, Nolde C, Büsche G, Buhr T, Kreipe H, Georgii A: Polycythaemia vera: Bone marrow histopathology under treatment with interferon, hydroxyurea and busulphan. Eur J Haematol 2000;64:32–41.
22.
Thiele J, Kvasnicka HM, Schmitt-Graeff A, Zankovich R, Diehl V: Follow-up examinations including sequential bone marrow biopsies in essential thrombocythemia (ET): A retrospective clinicopathological study of 120 patients. Am J Hematol 2002;70:283–291.
23.
Kreft A, Burg J, Fischer T, Kirkpatrick CJ: Essential thrombocythemia terminating in pure erythroleukemia. Am J Hematol 2004;77:140.
24.
Annaloro C, Lambertenghi Deliliers G, Oriani A, Pozzoli E, Lambertenghi Deliliers D, Radaelli F, Faccini P: Prognostic significance of bone marrow biopsy in essential thrombocythemia. Haematologica 1999;84:17–21.
25.
Harrison CN, Gale RE, Machin SJ, Linch DC: A large proportion of patients with diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood 1999;93:417–424.
26.
Cervantes F, Alvarez-Larrán A, Talarn C, Gómez M: Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: Actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br J Haematol 2002;118:786–790.
27.
Ferraris AM, Mangerini R, Racchi O, Rapezzi D, Rolfo M, Casciaro S, Gaetani GF: Heterogeneity of clonal development in chronic myeloproliferative disorders. Am J Hematol 1999;60:158–160.
28.
Kreipe H, Jaquet K, Felgner J, Radzun HJ, Parwaresch MR: Clonal granulocytes and bone marrow cells in the cellular phase of agnogenic myeloid metaplasia. Blood 1991;78:1814–1817.
29.
Buhr T, Büsche G, Choritz H, Länger F, Kreipe H: Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced by sequential bone marrow biopsies. Am J Clin Pathol 2002;119:152–158.
30.
Thiele J, Kvasnicka HM, Schmitt-Graeff A, Diehl V: Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: A follow-up study on 309 patients. Leuk Lymphoma 2003;44:949–953.
31.
Ellis JT, Peterson P, Geller SA, Rappaport H: Studies of the bone marrow in polycythemia vera and evolution of myelofibrosis and second hematologic malignancies. Semin Hematol 1986;23:144–155.
32.
Najean Y, Dresch C, Rain J-D: The very long-term course of polycythaemia: A complement to the previously published data of the Polycythaemia Vera Study Group. Br J Haematol 1994;86:233–235.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.